Sign in or create an account to add this stock to your watchlist.
About Ophthotech (NASDAQ:OPHT)
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula. Ophthotech Corporation has a research agreement with the University of Massachusetts Medical School to utilize the minigene therapy approach and novel gene delivery technologies to target retinal diseases. The company was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OPHT
CUSIPN/A
Phone212-845-8200
Debt
Debt-to-Equity RatioN/A
Current Ratio18.62
Quick Ratio18.62
Price-To-Earnings
Trailing P/E Ratio0.88
Forward P/E Ratio-1.71
P/E GrowthN/A
Sales & Book Value
Annual Sales$209.98 million
Price / Sales0.48
Cash Flow$3.1591 per share
Price / Cash0.88
Book Value$1.06 per share
Price / Book2.62
Profitability
EPS (Most Recent Fiscal Year)$3.17
Net Income$114.20 million
Net Margins26.69%
Return on Equity-1,485.62%
Return on Assets79.93%
Miscellaneous
Employees38
Outstanding Shares36,190,000
Ophthotech (NASDAQ:OPHT) Frequently Asked Questions
What is Ophthotech's stock symbol?
Ophthotech trades on the NASDAQ under the ticker symbol "OPHT."
How were Ophthotech's earnings last quarter?
Ophthotech (NASDAQ:OPHT) issued its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.40) by $0.04. Ophthotech had a negative return on equity of 1,485.62% and a net margin of 26.69%. View Ophthotech's Earnings History.
When is Ophthotech's next earnings date?
What price target have analysts set for OPHT?
2 brokers have issued 1 year price objectives for Ophthotech's shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Ophthotech's stock price to reach $4.00 in the next twelve months. View Analyst Ratings for Ophthotech.
Who are some of Ophthotech's key competitors?
Some companies that are related to Ophthotech include ProMetic Life Sciences (PFSCF), Kala Pharmaceuticals (KALA), MediciNova (MNOV), Merus (MRUS), Synergy Pharmaceuticals (SGYP), American Brivision (Holding) (ABVC), Syros Pharmaceuticals (SYRS), Cara Therapeutics (CARA), Albireo (ALBO), Innovate (INNT), Evolus (EOLS), Paratek Pharmaceuticals (PRTK), Corbus Pharmaceuticals (CRBP), Strongbridge Biopharma (SBBP) and Unum Therapeutics (UMRX).
Who are Ophthotech's key executives?
Ophthotech's management team includes the folowing people:
- Dr. David R. Guyer, Chairman and Chief Exec. Officer (Age 58)
- Mr. Glenn P. Sblendorio M.B.A., CEO, Pres & Director (Age 62)
- Dr. Samir C. Patel M.D., Co-Founder and Consultant (Age 57)
- Dr. Michael J. Ross, Director (Age 69)
- Mr. David F. Carroll M.B.A., CFO & Treasurer (Age 52)
Has Ophthotech been receiving favorable news coverage?
News coverage about OPHT stock has been trending somewhat positive on Monday, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ophthotech earned a coverage optimism score of 0.01 on Accern's scale. They also assigned headlines about the biopharmaceutical company an impact score of 44.49 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Ophthotech's major shareholders?
Ophthotech's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tamarack Advisers LP (2.35%), Dimensional Fund Advisors LP (1.56%), Spark Investment Management LLC (1.18%), Municipal Employees Retirement System of Michigan (1.06%), Millennium Management LLC (0.94%) and GSA Capital Partners LLP (0.62%). Company insiders that own Ophthotech stock include A/S Novo, Axel Bolte, Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio, Henric Bjorn Bjarke, Keith Westby and Samir Chandrakant Patel. View Institutional Ownership Trends for Ophthotech.
Which institutional investors are selling Ophthotech stock?
OPHT stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Russell Investments Group Ltd. and A.R.T. Advisors LLC. Company insiders that have sold Ophthotech company stock in the last year include Barbara A Wood, David E Redlick, David Francis Carroll, David R Guyer, Glenn Sblendorio and Keith Westby. View Insider Buying and Selling for Ophthotech.
Which institutional investors are buying Ophthotech stock?
OPHT stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Dimensional Fund Advisors LP, GSA Capital Partners LLP, Spark Investment Management LLC, Tamarack Advisers LP, Alambic Investment Management L.P. and Northern Trust Corp. View Insider Buying and Selling for Ophthotech.
How do I buy shares of Ophthotech?
Shares of OPHT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ophthotech's stock price today?
One share of OPHT stock can currently be purchased for approximately $2.78.
How big of a company is Ophthotech?
Ophthotech has a market capitalization of $103.86 million and generates $209.98 million in revenue each year. The biopharmaceutical company earns $114.20 million in net income (profit) each year or $3.17 on an earnings per share basis. Ophthotech employs 38 workers across the globe.
How can I contact Ophthotech?
Ophthotech's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The biopharmaceutical company can be reached via phone at 212-845-8200 or via email at [email protected]
MarketBeat Community Rating for Ophthotech (OPHT)
MarketBeat's community ratings are surveys of what our community members think about Ophthotech and other stocks. Vote "Outperform" if you believe OPHT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPHT will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ophthotech (NASDAQ:OPHT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Ophthotech in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 43.88%. The high price target for OPHT is $4.00 and the low price target for OPHT is $4.00. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 1.50 | 1.50 | 2.00 | 2.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
12 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.00 | $4.00 | $4.00 | $10.00 |
| Price Target Upside: | 43.88% upside | 31.15% upside | 43.37% upside | 258.42% upside |
Ophthotech (NASDAQ:OPHT) Consensus Price Target History
Ophthotech (NASDAQ:OPHT) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Ophthotech (NASDAQ:OPHT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ophthotech (NASDAQ OPHT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.00%
Institutional Ownership Percentage: 58.72%
Ophthotech (NASDAQ OPHT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Glenn Sblendorio | Insider | Sell | 6,838 | $2.69 | $18,394.22 | 55,245 |  |
| 1/5/2018 | Barbara A Wood | SVP | Sell | 602 | $3.17 | $1,908.34 | 17,064 | |
| 1/5/2018 | David R Guyer | Insider | Sell | 3,798 | $3.17 | $12,039.66 | 42,458 | |
| 1/5/2018 | Keith Westby | COO | Sell | 317 | $3.17 | $1,004.89 | 25,300 | |
| 1/3/2018 | Keith Westby | COO | Sell | 356 | $3.24 | $1,153.44 | 24,956 | |
| 1/2/2018 | Barbara A Wood | SVP | Sell | 5,289 | $3.19 | $16,871.91 | 20,472 | |
| 1/2/2018 | David R Guyer | Insider | Sell | 16,520 | $3.19 | $52,698.80 | 50,494 | |
| 1/2/2018 | Glenn Sblendorio | CEO | Sell | 8,089 | $3.19 | $25,803.91 | 44,584 | |
| 7/5/2017 | Barbara A Wood | SVP | Sell | 5,119 | $2.58 | $13,207.02 | 13,451 | |
| 7/5/2017 | David Francis Carroll | CFO | Sell | 3,284 | $2.58 | $8,472.72 | 7,500 | |
| 7/5/2017 | David R Guyer | Chairman | Sell | 17,678 | $2.58 | $45,609.24 | 37,692 | |
| 7/5/2017 | Glenn Sblendorio | CEO | Sell | 7,828 | $2.58 | $20,196.24 | 31,992 | |
| 6/13/2017 | David E Redlick | Director | Sell | 700 | $2.52 | $1,764.00 | 1,050 | |
| 4/3/2017 | Glenn Sblendorio | CFO | Sell | 7,388 | $3.56 | $26,301.28 | | |
| 1/5/2017 | David R Guyer | CEO | Sell | 3,785 | $4.96 | $18,773.60 | 10,997 | |
| 1/5/2017 | Henric Bjorn Bjarke | SVP | Sell | 316 | $4.96 | $1,567.36 | 1,700 | |
| 1/5/2017 | Samir Chandrakant Patel | President | Sell | 3,844 | $4.96 | $19,066.24 | 18,332 | |
| 1/3/2017 | Barbara A Wood | SVP | Sell | 675 | $4.90 | $3,307.50 | 1,375 | |
| 1/3/2017 | David R Guyer | CEO | Sell | 3,484 | $4.90 | $17,071.60 | 8,231 | |
| 1/3/2017 | Samir Chandrakant Patel | President | Sell | 2,999 | $4.90 | $14,695.10 | 16,406 | |
| 12/23/2016 | Barbara A. Wood | SVP | Sell | 746 | $4.92 | $3,670.32 | | |
| 12/22/2016 | Glenn Sblendorio | CFO | Sell | 1,079 | $4.85 | $5,233.15 | | |
| 12/15/2016 | A/S Novo | Major Shareholder | Sell | 3,610,487 | $4.87 | $17,583,071.69 | 1,405,487 | |
| 11/1/2016 | David R Guyer | CEO | Sell | 22,060 | $35.61 | $785,556.60 | 24,541 | |
| 10/3/2016 | David R Guyer | CEO | Sell | 22,060 | $44.37 | $978,802.20 | 24,541 | |
| 9/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $55.17 | $1,103,400.00 | 24,239 | |
| 8/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $52.80 | $1,056,000.00 | | |
| 8/1/2016 | David R Guyer | CEO | Sell | 24,060 | $64.47 | $1,551,148.20 | 56,451 | |
| 7/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $64.21 | $1,284,200.00 | 176,031 | |
| 7/1/2016 | David R Guyer | CEO | Sell | 24,060 | $52.12 | $1,254,007.20 | 56,451 | |
| 6/30/2016 | Samir Chandrakant Patel | President | Sell | 41,846 | $51.23 | $2,143,770.58 | 174,992 | |
| 6/3/2016 | Axel Bolte | Director | Buy | 3,500 | $56.97 | $199,395.00 | 6,000 | |
| 6/2/2016 | Glenn Sblendorio | CFO | Sell | 671 | $57.20 | $38,381.20 | 1,750 | |
| 6/1/2016 | David R Guyer | CEO | Sell | 30,060 | $52.71 | $1,584,462.60 | 62,451 | |
| 5/31/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $53.32 | $1,066,400.00 | 213,377 | |
| 5/24/2016 | A/S Novo | Major Shareholder | Sell | 1,300,000 | $49.00 | $63,700,000.00 | 3,610,489 | |
| 5/2/2016 | David R Guyer | CEO | Sell | 22,060 | $46.18 | $1,018,730.80 | 54,451 | |
| 4/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $46.79 | $935,800.00 | 231,008 | |
| 4/1/2016 | David R Guyer | CEO | Sell | 22,060 | $44.11 | $973,066.60 | 54,451 | |
| 3/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $41.85 | $837,000.00 | 248,410 | |
| 3/1/2016 | David R Guyer | CEO | Sell | 22,060 | $45.48 | $1,003,288.80 | 54,451 | |
| 2/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $45.13 | $902,600.00 | 263,736 | |
| 1/29/2016 | Samir Chandrakant Patel | President | Sell | 20,000 | $53.59 | $1,071,800.00 | 260,911 | |
| 1/28/2016 | David R. Guyer | CEO | Sell | 18,598 | $53.63 | $997,410.74 | 32,391 | |
| 1/11/2016 | Nicholas Galakatos | Director | Sell | 3,000 | $65.72 | $197,160.00 | 5,684 | |
| 1/4/2016 | Barbara A. Wood | SVP | Sell | 1,000 | $76.37 | $76,370.00 | 746 | |
| 12/30/2015 | David R. Guyer | CEO | Sell | 18,582 | $78.82 | $1,464,633.24 | 29,910 | |
| 12/30/2015 | Glenn Sblendorio | Director | Sell | 2,000 | $80.00 | $160,000.00 | | |
| 12/29/2015 | Samir Chandrakant Patel | President | Sell | 1,184 | $77.50 | $91,760.00 | 278,605 | |
| 12/24/2015 | Samir Chandrakant Patel | President | Sell | 26,036 | $77.09 | $2,007,115.24 | 278,605 | |
| 12/10/2015 | Nicholas Galakatos | Director | Sell | 3,000 | $64.44 | $193,320.00 | 7,684 | |
| 12/1/2015 | Barbara A. Wood | SVP | Sell | 2,000 | $63.24 | $126,480.00 | | |
| 11/30/2015 | David R. Guyer | CEO | Sell | 18,582 | $62.49 | $1,161,189.18 | 29,910 | |
| 11/24/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $60.27 | $1,640,248.05 | 278,605 | |
| 11/18/2015 | Nicholas Galakatos | Director | Sell | 1,500 | $60.00 | $90,000.00 | 9,684 | |
| 11/5/2015 | Samir Chandrakant Patel | President | Sell | 20,687 | $53.55 | $1,107,788.85 | 278,605 | |
| 10/21/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $43.27 | $1,177,593.05 | 259,292 | |
| 10/16/2015 | Barbara A. Wood | SVP | Sell | 2,000 | $45.00 | $90,000.00 | | |
| 9/29/2015 | David R. Guyer | CEO | Sell | 18,582 | $37.69 | $700,355.58 | 29,910 | |
| 9/21/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $46.34 | $1,261,143.10 | 259,292 | |
| 8/31/2015 | David R. Guyer | CEO | Sell | 18,582 | $44.88 | $833,960.16 | 29,910 | |
| 8/20/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $48.75 | $1,326,731.25 | 259,292 | |
| 7/20/2015 | Samir Chandrakant Patel | President | Sell | 27,215 | $67.87 | $1,847,082.05 | | |
| 7/17/2015 | Glenn Sblendorio | Director | Sell | 3,000 | $67.33 | $201,990.00 | | |
| 7/1/2015 | Barbara A Wood | SVP | Sell | 2,000 | $51.94 | $103,880.00 | | |
| 6/29/2015 | David R Guyer | CEO | Sell | 18,582 | $51.05 | $948,611.10 | | |
| 6/18/2015 | Samir Chandrakant Patel | President | Sell | 12,000 | $49.78 | $597,360.00 | | |
| 5/28/2015 | David R Guyer | CEO | Sell | 18,582 | $48.62 | $903,456.84 | | |
| 4/29/2015 | David R Guyer | CEO | Sell | 18,582 | $48.45 | $900,297.90 | | |
| 4/17/2015 | Samir Chandrakant Patel | President | Sell | 12,000 | $50.47 | $605,640.00 | | |
| 3/30/2015 | Axel Bolte | Director | Buy | 500 | $48.27 | $24,135.00 | | |
| 3/30/2015 | David R Guyer | CEO | Sell | 18,582 | $48.26 | $896,767.32 | | |
| 3/2/2015 | Barbara A Wood | SVP | Sell | 2,000 | $53.26 | $106,520.00 | | |
| 3/2/2015 | David R Guyer | CEO | Sell | 18,582 | $53.22 | $988,934.04 | | |
| 1/2/2015 | David R Guyer | CEO | Sell | 15,034 | $45.34 | $681,641.56 | | |
| 11/13/2014 | A/S Novo | Major Shareholder | Sell | 995,000 | $40.20 | $39,999,000.00 | | |
| 11/3/2014 | David R Guyer | CEO | Sell | 15,034 | $39.71 | $597,000.14 | | |
| 10/2/2014 | David R Guyer | CEO | Sell | 2,807 | $38.52 | $108,125.64 | | |
| 10/2/2014 | Samir Chandrakant Patel | President | Sell | 1,965 | $38.04 | $74,748.60 | | |
| 10/1/2014 | David R Guyer | CEO | Sell | 12,227 | $37.30 | $456,067.10 | | |
| 10/1/2014 | Samir Chandrakant Patel | President | Sell | 17,676 | $37.28 | $658,961.28 | | |
| 9/4/2014 | David R Guyer | CEO | Sell | 1,107 | $38.58 | $42,708.06 | | |
| 8/1/2014 | Bruce Peacock | CFO | Sell | 6,191 | $37.78 | $233,895.98 | | |
| 8/1/2014 | David R Guyer | CEO | Sell | 13,136 | $37.85 | $497,197.60 | | |
| 8/1/2014 | Samir Chandrakant Patel | President | Sell | 18,986 | $37.80 | $717,670.80 | | |
| 7/1/2014 | Bruce Peacock | CFO | Sell | 7,739 | $41.07 | $317,840.73 | | |
| 7/1/2014 | David R Guyer | CEO | Sell | 15,034 | $41.08 | $617,596.72 | | |
| 7/1/2014 | Samir Chandrakant Patel | President | Sell | 18,986 | $41.08 | $779,944.88 | | |
| 6/16/2014 | Nicholas Galakatos | Director | Sell | 144,976 | $44.17 | $6,403,589.92 | | |
| 6/11/2014 | Lifesciences Ii L.P. Clarus | Major Shareholder | Sell | 211,680 | $45.42 | $9,614,505.60 | | |
| 6/4/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,966,935 | $42.54 | $83,673,414.90 | | |
| 6/3/2014 | Bruce Peacock | CFO | Sell | 13,931 | $40.12 | $558,911.72 | | |
| 6/3/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 1,865,619 | $40.65 | $75,837,412.35 | | |
| 6/2/2014 | David R Guyer | CEO | Sell | 25,417 | $39.92 | $1,014,646.64 | | |
| 6/2/2014 | Samir Chandrakant Patel | President | Sell | 27,873 | $39.91 | $1,112,411.43 | | |
| 5/30/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 931,869 | $40.99 | $38,197,310.31 | | |
| 5/28/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 980,127 | $40.19 | $39,391,304.13 | | |
| 5/23/2014 | Svlsf Iv, Llc | Major Shareholder | Sell | 330,450 | $38.10 | $12,590,145.00 | | |
| 5/13/2014 | Hbm Healthcare Investments (Ca | major shareholder | Sell | 500,000 | $29.75 | $14,875,000.00 | 3,139,902 | |
| 5/1/2014 | Bruce Peacock | CFO | Sell | 4,643 | $32.43 | $150,572.49 | | |
| 5/1/2014 | David Guyer | CEO | Sell | 10,665 | $33.71 | $359,517.15 | 11,891 | |
| 5/1/2014 | Samir Chandrakant Patel | President | Sell | 14,319 | $32.45 | $464,651.55 | 104,472 | |
| 3/24/2014 | Bruce Peacock | CFO | Sell | 6,137 | $34.77 | $213,383.49 | | |
| 3/24/2014 | David Guyer | CEO | Sell | 12,027 | $34.53 | $415,292.31 | 34,583 | |
| 3/24/2014 | Samir Chandrakant Patel | President | Sell | 16,876 | $34.54 | $582,897.04 | 135,667 | |
| 2/18/2014 | Svlsf Iv, Llc | major shareholder | Sell | 2,111,364 | $29.61 | $62,517,488.04 | 140,228 | |
| 9/30/2013 | A/S Novo | Insider | Buy | 455,000 | $22.00 | $10,010,000.00 | | |
| 9/30/2013 | Hbm Healthcare Investments (Ca | Major Shareholder | Buy | 228,000 | $22.00 | $5,016,000.00 | | |
(Data available from 1/1/2013 forward)
Ophthotech (NASDAQ OPHT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Zacks: Brokerages Anticipate Ophthotech (OPHT) to Post -$0.40 Earnings Per Share
www.americanbankingnews.com - May 19 at 5:25 AM |
 | Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels ...
www.nasdaq.com - May 14 at 5:25 PM |
 | Form DEFA14A Ophthotech Corp.
www.streetinsider.com - May 14 at 5:25 PM |
| Ophthotech (OPHT) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 14 at 12:13 PM |
 | Recent Analysis Shows PHH, Stanley Black & Decker, Invacare, Ophthotech, Party City Holdco, and Hyatt Hotels Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - May 14 at 8:18 AM |
| Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus
www.nasdaq.com - May 10 at 6:05 PM |
| Edited Transcript of OPHT earnings conference call or presentation 9-May-18 12:00pm GMT
finance.yahoo.com - May 10 at 8:17 AM |
| Ophthotech (OPHT) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 8:52 PM |
 | Ophthotech's (OPHT) CEO Glenn Sblendorio on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 5:40 PM |
| Ophthotech Corp (OPHT) Tops Q1 EPS by 4c
www.streetinsider.com - May 9 at 8:12 AM |
| Ophthotech Reports First Quarter 2018 Financial and Operating Results
finance.yahoo.com - May 9 at 8:12 AM |
| Ophthotech: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 8:12 AM |
| Wired News – Ophthotech Announced Completion of Patient Enrollment in Phase-2a Clinical Trial of Zimura(R) in Wet Age-Related Macular Degeneration
finance.yahoo.com - May 3 at 8:09 AM |
| Ophthotech (OPHT) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 1:56 PM |
 | BRIEF-Ophthotech Completes Patient Recruitment In A Mid-Stage Trial Of Its Eye Drug Zimura
www.reuters.com - May 1 at 8:16 AM |
 | Ophthotech Completes Patient Recruitment in the Phase 2a Clinical Trial of Zimura
www.businesswire.com - May 1 at 8:16 AM |
| Ophthotech (OPHT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 30 at 5:34 PM |
| Ophthotech (OPHT) Upgraded to "Buy" at ValuEngine
www.americanbankingnews.com - April 8 at 11:17 AM |
| Ophthotech (OPHT) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 5:40 PM |
| Insider Selling: Ophthotech (OPHT) Insider Sells 6,838 Shares of Stock
www.americanbankingnews.com - April 3 at 11:04 PM |
| Ophthotech (OPHT) Rating Lowered to D+ at TheStreet
www.americanbankingnews.com - March 24 at 12:11 PM |
| Regeneron Eylea Hits 24-Week Primary Endpoint in Study - Nasdaq ... - Nasdaq
www.nasdaq.com - March 21 at 8:40 AM |
| Regeneron Eylea Hits 24-Week Primary Endpoint in Study
finance.yahoo.com - March 21 at 8:39 AM |
 | Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In ... - Benzinga
www.benzinga.com - March 20 at 8:19 AM |
| Ophthotech (OPHT) Rating Lowered to Underweight at JPMorgan Chase & Co.
www.americanbankingnews.com - March 19 at 10:59 AM |
| Ophthotech Corp (OPHT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 11 at 6:18 PM |
| Ophthotech (OPHT) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 7 at 12:49 PM |
| Stonepine Capital Management LLC Lowers Holdings in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 2:56 PM |
| Tamarack Advisers LP Has $2.34 Million Position in Ophthotech Corp (OPHT)
www.americanbankingnews.com - March 6 at 10:30 AM |
| Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference - Business Wire (press release)
www.businesswire.com - March 6 at 8:09 AM |
| Ophthotech to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 8:09 AM |
| Ophthotech Corp (OPHT) Position Reduced by Bogle Investment Management L P DE
www.americanbankingnews.com - March 6 at 5:04 AM |
| Ophthotech (OPHT) Downgraded by ValuEngine to Hold
www.americanbankingnews.com - March 4 at 12:48 PM |
| Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results - Business Wire (press release)
www.businesswire.com - March 1 at 8:09 AM |
| Ophthotech's (OPHT) CEO Glenn Sblendorio on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 1 at 8:09 AM |
| Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus - Nasdaq
www.nasdaq.com - March 1 at 8:09 AM |
| Blog Exposure - Ophthotech Initiates Research Collaborations to Discover Treatments for Orphan and Age-Related Retinal Diseases
finance.yahoo.com - March 1 at 8:09 AM |
| Ophthotech (OPHT) Given New $4.00 Price Target at Chardan Capital
www.americanbankingnews.com - February 28 at 4:34 PM |
 | Ophthotech (OPHT) Q4 Earnings Beat, Gene Therapy in Focus
www.zacks.com - February 28 at 8:11 AM |
| Ophthotech Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
finance.yahoo.com - February 27 at 5:59 PM |
| Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy
finance.yahoo.com - February 27 at 5:59 PM |
| Ophthotech (OPHT) Announces Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - February 27 at 9:12 AM |
| Ophthotech Targets Gene Therapy to Expand its Orphan and Age-Related Retinal Disease Strategy - Business Wire (press release)
www.businesswire.com - February 27 at 8:12 AM |
| Ophthotech (OPHT) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 22 at 1:16 PM |
| Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)
www.businesswire.com - February 21 at 8:15 AM |
| Ophthotech Corporation to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, February 27, 2018
finance.yahoo.com - February 21 at 8:15 AM |
| Ophthotech Corp (OPHT) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 14 at 5:34 PM |
| Ophthotech Corp (OPHT) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 20 at 5:38 PM |
| Ophthotech Begins Phase II Zimura Study in Stargardt Disease
www.zacks.com - January 17 at 10:10 AM |
| Ophthotech Announces Election of Jane Pritchett Henderson, Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, to Its Board of ...
www.businesswire.com - January 16 at 4:38 PM |
Ophthotech (NASDAQ:OPHT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ophthotech (NASDAQ:OPHT) Income Statement, Balance Sheet and Cash Flow Statement
Ophthotech (NASDAQ OPHT) Stock Chart for Monday, May, 21, 2018
Loading chart…
